Table 2—

Proportion of subjects progressing to diabetes, months until progression, and rate of progression, by IFG stage

Added IFG subjects (100–109 mg/dl)
Original IFG subjects (110–125 mg/dl)
Total (all subjects)
Did not progress to original IFGProgressed to original IFGTotalInitial IFG stage was added IFGInitial IFG stage was original IFGTotal
n (%) 3,753 (82.9) 773 (17.1) 4,526 773 (45.5) 926 (54.5) 1,699 5,452 
Progressing to diabetes* 201 (5.4) 164 (21.2) 365 (8.1) 164 (21.2) 249 (26.8) 413 (24.3) 614 (11.3) 
Months from 1st FPG measure in stage to progression of diabetes* 31.1 ± 23.2 54.1 ± 27.6 41.4 ± 25.8 29.5 ± 25.9 28.7 ± 26.5 29.0 ± 26.2 36.3 ± 27.9 
Diabetes incidence per year* 0.91 3.24 1.34 5.16 5.87 5.56 1.95 
Added IFG subjects (100–109 mg/dl)
Original IFG subjects (110–125 mg/dl)
Total (all subjects)
Did not progress to original IFGProgressed to original IFGTotalInitial IFG stage was added IFGInitial IFG stage was original IFGTotal
n (%) 3,753 (82.9) 773 (17.1) 4,526 773 (45.5) 926 (54.5) 1,699 5,452 
Progressing to diabetes* 201 (5.4) 164 (21.2) 365 (8.1) 164 (21.2) 249 (26.8) 413 (24.3) 614 (11.3) 
Months from 1st FPG measure in stage to progression of diabetes* 31.1 ± 23.2 54.1 ± 27.6 41.4 ± 25.8 29.5 ± 25.9 28.7 ± 26.5 29.0 ± 26.2 36.3 ± 27.9 
Diabetes incidence per year* 0.91 3.24 1.34 5.16 5.87 5.56 1.95 

Data are n (%), means ± SD, or percent.

*

Among added IFG subjects, those who did and did not progress to original IFG differ significantly: P < 0.0001.

Among original IFG subjects, those whose initial IFG stage was added vs. original IFG differ significantly: P = 0.007.

Total added and original IFG subjects differ significantly: P < 0.0001.

Close Modal

or Create an Account

Close Modal
Close Modal